CUSIP
No. 45168K405
|
|
1
|
NAMES OF REPORTING PERSONS
Baker Bros. Advisors LP
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(a)
¨
(b)
¨
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
2,066,535 (1)
|
6
|
SHARED VOTING POWER
-0-
|
7
|
SOLE DISPOSITIVE POWER
2,066,535 (1)
|
8
|
SHARED DISPOSITIVE POWER
-0-
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,066,535 (1)
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.9% (1)(2)
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
IA, PN
|
|
(1)
|
Includes 19,355 shares of the common stock (“Common Stock”) of Idera Pharmaceuticals, Inc. (the “Issuer”)
issuable upon the conversion or exercise of Derivative Securities (as defined in Item 4) of the Issuer.
|
|
(2)
|
Based on 42,273,104 shares of the Common Stock of the Issuer outstanding as of March 19, 2021, as per information received from the
Issuer.
|
CUSIP
No. 45168K405
|
|
1
|
NAMES OF REPORTING PERSONS
Baker Bros. Advisors (GP) LLC
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(a)
¨
(b)
¨
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
2,066,535 (1)
|
6
|
SHARED VOTING POWER
-0-
|
7
|
SOLE DISPOSITIVE POWER
2,066,535 (1)
|
8
|
SHARED DISPOSITIVE POWER
-0-
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,066,535 (1)
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.9% (1)(2)
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
HC, OO
|
|
(1)
|
Includes 19,355 shares of Common Stock of the Issuer issuable upon the conversion or exercise of Derivative Securities (as defined
in Item 4) of the Issuer.
|
|
(2)
|
Based on 42,273,104 shares of the Common Stock of the Issuer outstanding as of March 19, 2021, as per information received from the
Issuer.
|
CUSIP
No. 45168K405
|
|
1
|
NAMES OF REPORTING PERSONS
Felix J. Baker
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(a)
¨
(b)
¨
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
2,088,464 (1)
|
6
|
SHARED VOTING POWER
-0-
|
7
|
SOLE DISPOSITIVE POWER
2,088,464 (1)
|
8
|
SHARED DISPOSITIVE POWER
-0-
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,088,464 (1)
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.9% (1)(2)
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
IN, HC
|
|
(1)
|
Includes 19,355 shares of Common Stock of the Issuer issuable upon the conversion or exercise of Derivative Securities (as defined
in Item 4) of the Issuer.
|
|
(2)
|
Based on 42,273,104 shares of the Common Stock of the Issuer outstanding as of March 19, 2021, as per information received from the
Issuer.
|
CUSIP
No. 45168K405
|
|
1
|
NAMES OF REPORTING PERSONS
Julian C. Baker
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(a)
¨
(b)
¨
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
2,088,464 (1)
|
6
|
SHARED VOTING POWER
-0-
|
7
|
SOLE DISPOSITIVE POWER
2,088,464 (1)
|
8
|
SHARED DISPOSITIVE POWER
-0-
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,088,464 (1)
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.9% (1)(2)
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
IN, HC
|
|
(1)
|
Includes 19,355 shares of Common Stock of the Issuer issuable upon the conversion or exercise of Derivative Securities (as defined
in Item 4) of the Issuer.
|
|
(2)
|
Based on 42,273,104 shares of the Common Stock of the Issuer outstanding as of March 19, 2021, as per information received from the
Issuer.
|
CUSIP
No. 45168K405
|
|
1
|
NAMES OF REPORTING PERSONS
FBB3 LLC
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
|
(a)
¨
(b)
¨
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
4,112 (1)
|
6
|
SHARED VOTING POWER
-0-
|
7
|
SOLE DISPOSITIVE POWER
4,112 (1)
|
8
|
SHARED DISPOSITIVE POWER
-0-
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,112 (1)
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions)
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
0.01% (1)(2)
|
12
|
TYPE OF REPORTING PERSON (See Instructions)
OO
|
|
(1)
|
Includes 4,112 shares of Common Stock of the Issuer issuable upon the conversion or exercise of Derivative Securities (as defined
in Item 4) of the Issuer.
|
|
(2)
|
Based on 42,273,104 shares of the Common Stock of the Issuer outstanding as of March 19, 2021, as per information received from the
Issuer.
|
Amendment No. 2 to Schedule 13G
This Amendment No. 2 to Schedule 13G amends the previously filed Schedule
13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian
C. Baker, Felix J. Baker and FBB3 LLC (“FBB3”, and together with the Adviser, the Adviser GP, Julian C. Baker and Felix J.
Baker, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain
in full force and effect.
|
Item 1(a)
|
Name of Issuer:
|
Idera Pharmaceuticals, Inc.
|
Item 1(b)
|
Address of Issuer’s Principal Executive Offices:
|
505 Eagleview Blvd., Suite 212
Exton, Pennsylvania 19341
|
Item 2(a)
|
Name of Person Filing:
|
This Amendment No. 2 is being filed jointly
by the Reporting Persons.
|
Item 2(b)
|
Address of Principal Business Office or, if None, Residence:
|
The business address of each of the Reporting
Persons is:
c/o Baker Bros. Advisors LP
860 Washington Street, 3rd
Floor
New York, NY 10014
(212) 339-5690
The Adviser is a limited partnership organized under the laws
of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship
of each of Julian C. Baker and Felix J. Baker is the United States of America. FBB3 is a limited liability company organized under the
laws of the state of Delaware.
|
Item 2(d)
|
Title of Class of Securities:
|
Common Stock, par value $0.001
per share (“Common Stock”)
45168K405
|
Item 3.
|
If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:
|
(a) ¨ Broker or dealer registered
under Section 15 of the Exchange Act.
(b) ¨ Bank as defined in
section 3(a)(6) of the Exchange Act.
(c) ¨ Insurance company
as defined in section 3(a)(19) of the Exchange Act.
(d) ¨ Investment company
registered under section 8 of the Investment Company Act of 1940.
(e) x An investment adviser
in accordance with Rule 13d-1(b)(1)(ii)(E).
(f) ¨ An employee benefit
plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g) x A parent holding company
or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h) ¨ A savings association
as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i) ¨ A church plan that
is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
(j) ¨ Group, in accordance
with Rule 13d-1(b)(1)(ii)(J).
Items 5 through 9 and 11 of each of the cover pages to this Amendment
No. 2 are incorporated herein reference.
Set forth below is the aggregate number of shares of Common Stock directly
held by each of 667, L.P. (“667”) and Baker Brothers Life Sciences, L.P. (“Life Sciences”, and together with 667,
the “Funds”), which may be deemed to be indirectly beneficially owned by the Reporting Persons plus 19,355 shares of Common
Stock of the Issuer issuable upon the conversion or exercise of Derivative Securities (as defined in Item 4) of the Issuer.
The information set forth below is based upon 42,273,104 shares of
Common Stock outstanding as of March 19, 2021, as per information received from the Issuer. Such percentage figures are calculated in
accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.
Name
|
|
Number of
Shares of
Common
Stock we
own or have
to right
to acquire
within 60
days
|
|
|
Percent of Class
Outstanding
|
|
667, L.P.
|
|
|
237,699
|
|
|
|
0.6
|
%
|
Baker Brothers Life Sciences, L.P.
|
|
|
1,828,836
|
|
|
|
4.3
|
%
|
Total
|
|
|
2,066,535
|
|
|
|
4.9
|
%
|
Julian. C Baker and Felix J. Baker each hold 21,929 shares of Common
Stock.
In addition, the Funds and certain Reporting Persons directly hold
certain warrants to purchase Common Stock or convertible preferred stock of the Issuer (such warrants and convertible preferred stock,
collectively, the “Derivative Securities”). As reflected in the table above the Funds have a present right to acquire an aggregate
of 19,355 shares of Common Stock through the exercise or conversion of Derivative Securities. The remainder of the Derivative Securities
held by the Funds or certain other Reporting Persons do not currently represent beneficial ownership of the Common Stock for the Reporting
Persons because either the Derivative Securities or the underlying series of convertible preferred stock of the Issuer are subject to
beneficial ownership limitations on exercise or conversion such that the Reporting Persons do not have a present right to acquire shares
of Common Stock within 60 days.
The Adviser GP is the sole general partner of the Adviser. Pursuant
to the management agreements, as amended, among the Adviser, Life Sciences and 667 and their respective general partners, the Funds’ respective
general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities
held by the Funds, and thus the Adviser has completed and unlimited discretion and authority with respect to the Funds’ investments
and voting power over investments.
Julian C. Baker and Felix J. Baker are also the sole managers of FBB3
and by policy they do not transact in or vote the securities of the Issuer held by FBB3.
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
If this statement is being filed
to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of
the class of securities, check the following x.
|
Item 6.
|
Ownership of More than Five Percent on Behalf of Another
Person.
|
N/A
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
or Control Person.
|
The information in Item 4 is
incorporated herein by reference.
|
Item 8.
|
Identification and Classification of Members of the Group.
|
N/A
|
Item 9.
|
Notice of Dissolution of Group.
|
N/A
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete and correct.
April 9, 2021
|
BAKER BROS. ADVISORS LP
By: Baker Bros. Advisors (GP) LLC, its general partner
|
|
|
|
|
By:
|
/s/ Scott L. Lessing
|
|
|
Name: Scott L. Lessing
Title: President
|
|
BAKER BROS. ADVISORS (GP) LLC
|
|
|
|
|
By:
|
/s/ Scott L. Lessing
|
|
|
Name: Scott L. Lessing
Title: President
|
|
/s/ Julian C. Baker
|
|
Julian C. Baker
|
|
|
|
/s/ Felix J. Baker
|
|
Felix J. Baker
|
|
|
|
FBB3 LLC
|
|
/s/ Julian C. Baker
|
|
Julian C. Baker
|